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ABSTRACT.
Purpose: To study the association of the single nucleotide polymorphism (SNP)
rs4073 in the interleukin-8 (IL-8) promoter region with the diagnosis and age of
onset of exudative age-related macular degeneration (AMD) in association with
the known genetic risk factors for AMD and tobacco smoking.
Methods: Medical records, smoking history and angiograms or fundus photographs
of 301 patients with exudative AMD, 72 patients with dry AMD and 119 control
subjects were analysed retrospectively. The associations of IL-8 rs4073 A?T,CFH
rs1061170 T?C, ARMS2 rs10490924 G?T and C3 rs2230199 C?G SNPs with
the presence of AMD and with the age of onset of exudative AMD were analysed.
Results: Younger age of exudative AMD onset was associated with the
homozygous AA genotype of IL-8 rs4073 (p = 0.009, Mann–Whitney U-test),
CC genotype of CFH rs1061170 (p = 0.016), TT genotype of ARMS2
rs10490924 (p = 0.001) and with current smoking (p = 0.002). The risk alleles
C in CFH rs1061170 (p < 0.0001, Pearson chi-square) and T in ARMS2
rs10490924 (p < 0.0001), as well as smoking (p < 0.0001), were more prevalent
in AMD patients compared with controls. No association was found between the
IL-8 rs4073 genotype and the presence of AMD.
Conclusion: Out of the factors associated with the earlier onset of exudative
AMD, only the genotype of IL-8 rs4073 did not appear as a risk factor for AMD
in general. IL-8 may have a role in accelerating the development of the choroidal
neovascularization in exudative AMD.
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Introduction
Inﬂammation plays an important role
in the pathogenesis and progression of
age-related macular degeneration
(AMD). Higher circulatory levels of
inﬂammatory mediators C-reactive
protein (CRP) and interleukin-6 (IL-
6) have been shown to be associated
with the progression of AMD (Seddon
et al. 2005; Hong et al. 2011). Genetic
association studies have emphasized
the role of individual variations in the
alternative complement cascade in
increasing the risk of AMD develop-
ment (Edwards et al. 2005; Haines
et al. 2005; Klein et al. 2005; Gold
et al. 2006; Maller et al. 2006, 2007;
Yates et al. 2007; Seddon et al. 2013).
The role of interleukin-8 (IL-8) is more
controversial. Single nucleotide poly-
morphisms (SNPs) in the IL-8 gene
have been variably associated with the
prevalence of atrophic and exudative
AMD (Goverdhan et al. 2008; Tsai
et al. 2008; Ricci et al. 2013). The
intraocular IL-8 concentrations, how-
ever, have been elevated in patients
with exudative AMD (Jonas et al.
2012) and correlated with the size of
an active choroidal neovascularization
(CNV) and with the macular volume
after bevacizumab treatment (Roh
et al. 2009; Miao et al. 2012).
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Promoter region SNP IL-8 rs4073
A?T (-251A/T) has been connected to
the regulation of transcriptional activity
of the IL-8 gene and to the levels of IL-8
production (Hull et al. 2000; Ohyauchi
et al. 2005; Taguchi et al. 2005; Hilde-
brand et al. 2007). In our previous
studies in patients with exudative
AMD treated with bevacizumab, the
IL-8 rs4073 genotype was associated
with both the initial anatomic treatment
response and with the persistence of
intra- and subretinal ﬂuid in macular
optical coherence tomographies (OCTs)
during 2-year follow-up (Hautam€aki
et al. 2013, 2014). In that data, the risk
alleles of IL-8 rs4073 A?T and CFH
rs1061170 T?C were also associated
with earlier onset of exudative AMD
(data not published). Therefore, we
wanted to study further the association
of the IL-8 SNP with the prevalence of
AMD and with the age of onset of
exudative AMD in a larger patient
material, in association with the known
AMD risk SNPs CFH rs1061170 T?C
(Y402H), ARMS2 rs10490924 G?T
(LOC387715, A69S) and C3 rs2230199
C?G (R102G) previously found to be
associated with AMD also in the Finn-
ish population (Seitsonen et al. 2006,
2008).
Materials and Methods
The total number of 492 Finnish
subjects was included: 301 patients
with exudative AMD, 72 with dry
AMD and 119 control subjects. The
patients with exudative AMD, 90
control subjects and 28 patients with
dry AMD were recruited to our three
previous studies on AMD genetics
and treatment response in exudative
AMD from the Medical Retina (cases)
and Cataract Surgery (controls) units
of the Departments of Ophthalmology
of Helsinki (n = 368), Oulu (n = 6),
and Tampere (n = 1) University Hos-
pitals, or private oﬃces and outpa-
tient clinics (n = 44), between January
2003 and April 2010 (Seitsonen et al.
2006; Hautam€aki et al. 2013, 2014).
Additionally, 44 diabetic patients with
large drusenoid macular deposits vis-
ible in fundus photographs taken for
screening of diabetic (DM) retinopa-
thy between January 2006 and Febru-
ary 2007 were included in the analysis
of IL-8 rs4073 as having dry AMD,
and 29 men recruited between October
2004 and June 2007 to an ongoing
study of risk factors for AMD in a
cohort of male executives or academic
professionals, originally examined for
cardiovascular health, cognition and
quality of life (Strandberg et al. 2004),
were included as additional control
subjects.
The control group consisted of 119
subjects (74 female, 45 male) who were
>69 years of age, with no large drusen,
and no, or minimal focal pigmentary
abnormalities within the radius of one
disc diameter from the fovea in fundus
photographs graded according to the
AREDS classiﬁcation (Davis et al.
2005). The maximum total area of
pigment abnormalities corresponded
to a circle with diameter of 250 lm,
and a maximum of ﬁve hard small
(<63 lm) drusen was allowed. Sixty-
ﬁve subjects had neither pigment
abnormalities nor drusen, 50 had only
pigment abnormalities, three had only
small drusens, and one subject had
both drusens and pigment abnormali-
ties.
Patients with dry AMD were
>50 years of age (43 female, 29 male),
had at least 10 soft drusen >125 lm, a
conﬂuent area of drusen >1 disc area
within the radius of one disc diameter
from the fovea or a central geographic
atrophy related to AMD.
The diagnosis of exudative AMD
(204 female, 97 male) was made by an
experienced medical retina specialist.
The age of onset of exudative AMD
was determined as the age at the
diagnosis in cases with a recent onset
of symptoms based on the medical
records, and no substantial subretinal
ﬁbrosis detected in clinical examina-
tion or angiograms. The age of onset
of the exudative AMD in the ﬁrst
aﬀected eye was possible to determine
in 259 patients (259/303, 85%). In 42
patients, the diagnosis was considered
to be delayed: patients had been
symptomatic for longer than a year,
or the diagnosis was made only in a
late stage of the disease with subreti-
nal ﬁbrosis. In these patients, the age
of onset of the exudative AMD in the
ﬁrst eye could not be estimated, and
their data were included only in the
genetic analyses comparing AMD
patients with the control group. The
diagnosis of exudative AMD was
based on ﬂuorescein angiograms
(FA) in 253 patients. The CNV lesions
were classiﬁed according to the TAP-
study criteria (Barbazetto et al. 2003);
39 were predominantly classic
(15.1%), 129 occult (50.0%), 53 min-
imally classic (20.5%), 1 polypoidal
(0.4%) and 23 not deﬁned (>50% of
the lesion area composed of haemor-
rhage or serous pigment epithelial
detachment, 8.9%). In eight patients
(3.1%), the angiograms were recorded,
but were not available for retrospec-
tive analysis, and no classiﬁcation of
the lesion was found in the medical
records. Five patients had received no
treatment (poor visual acuity in four
patients and a pigment epithelial tear
in one patient), and FAs were, there-
fore, not recorded.
The patients were classiﬁed as
never, ex- or current smokers. Never
smokers were determined as having
smoked less than one pack-year, ex-
smokers as having quit smoking at
least 10 years ago. If a participant had
ever smoked, the smoking pack-years
were calculated (pack-year = [cigarettes
per day] 9 [years of smoking]/[20 cig-
arettes per pack]).
The study protocol adhered to the
tenets of the Declaration of Helsinki
and was approved by the local ethics
committee. A written informed consent
was obtained from all participants.
SNP genotyping
The blood DNA samples of the patients
and control subjects (301 exudative
AMD, 28 dry AMD patients and 119
controls) were analysed for the SNPs
IL-8 rs4073 A?T, CFH rs1061170 T?
C, ARMS2rs10490924 G?T and C3
rs2230199 C?G (Seitsonen et al. 2008;
Hautam€aki et al. 2013), except for the
additional 44 samples of dry AMD
patients recruited from photographic
screening of DM retinopathy, which
were analysed only for the IL-8 rs4073.
The SNP analyses were carried out
using phenol–chloroform extraction
for DNA and PCR-based genotyping
with BIG DYE TERMINATOR v3.1 Cycle
Sequencing kit (Applied Biosystems,
Foster City, CA, USA) as described
before. (Seitsonen et al. 2008; Hauta-
m€aki et al. 2013). The DNA
fragments were puriﬁed from excess
dye terminators with PERFORMA
DTR v3 ﬁlter plates (Edge Biosys-
tems, Gaithersburg, MD, USA) and
resolved on an ABI 3730 capillary
sequencer. All the methods were
used as recommended by the
manufacturer.
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Statistical analysis
IBM SPSS Statistics version 22 (IBM
Corp., Armonk, NY, USA) was used
for statistical testing. Non-parametric
tests were used in univariate compari-
sons between the groups. The simulta-
neous eﬀects of genetic markers and
smoking on the diagnosis and the age
of onset of exudative AMD were esti-
mated ﬁrst with multivariate models
built with the generalized linear model
(GLZ) procedure in SPSS 22. To take
into account the diﬀerences in the age
distributions in the patients and con-
trol subjects, the eﬀects of the studied
variables were also estimated with the
Cox regression analysis as suggested by
van der Net and associates (2008). The
use of Cox regression in cross-sectional
genetic association studies is based on
the principle that as the genotype status
does not change over time, age at event
can be considered as follow-up time
(van der Net et al. 2008). A two-tailed
p-value <0.05 was considered statisti-
cally signiﬁcant, no correction for
multiple comparisons was used. We
estimated that with this sample size
13% diﬀerences in allele frequencies
between the groups, and diﬀerence of
3 years in the age of onset could be
detected with a power of 0.8 and a
p-value of 0.05 (calculator for
sample size provided at https://
www.statstodo.com/).
Results
We ﬁrst analysed the associations of
the genotypes of IL-8 rs4073, CFH
rs1061170, ARMS2 rs10490924 and
C3 rs2230199 and smoking behaviour
with the diagnosis of any AMD or
exudative AMD in the whole study
population.
As reported before for a subgroup of
the patients included in the analyses,
also in this combined sample the risk
alleles C inCFH rs1061170 (p < 0.0001,
Pearson chi-square) and T in ARMS2
rs10490924 (p < 0.0001), as well as
smoking (p < 0.0001), were more pre-
valent both in the exudative AMD
group and in all AMD patients com-
pared with the control group (Table 1)
(Seitsonen et al. 2006, 2008). No signif-
icant diﬀerences were found in the
frequencies of IL-8 rs4073 or C3
rs2230199 genotypes between the
groups. The eﬀects of the studied SNPs
and smoking remained unchanged in
multivariate modelling (GLZ, data not
shown).
We then analysed the associations of
the studied factors with the age of onset
of exudative AMD including only
patients with exudative AMD in the
analyses. The eﬀects of the homozygous
risk genotypes AA in IL-8 rs4073, CC in
CFH rs1061170 and TT in ARMS2
rs10490924, as well as smoking were
signiﬁcant both in the univariate com-
parisons between the groups (Table 2)
and in the conventional multivariate
modelling with the GLZ (Table 3).
Table 1. Genotype frequencies and smoking history in exudative age-related macular degener-
ation (AMD) patients and all AMD patients (dry or exudative) compared with control subjects.
Polymorphisms
Controls
(n = 119)
Exudative AMD
(n = 301)
Pearson
chi-square
Any AMD
(n = 373)
Pearson
chi-square
IL-8 rs4073 A?T
AA 26 (21.8%) 45 (15.0%) p = 0.120 61 (16.4%) p = 0.275
AT 52 (43.7%) 161 (53.5%) 190 (50.9%)
TT 41 (34.5%) 95 (31.6%) 122 (32.7%)
NA 0 0 0
CFH rs1061170 T?C
CC 13 (11.5%) 109 (36.2%) p < 0.0001 129 (39.2%) p < 0.0001
CT 59 (52.2%) 154 (51.2%) 162 (49.2%)
TT 41 (36.3%) 38 (12.6%) 38 (11.6%)
NA 6 0 44
ARMS2 rs10490924 G?T
TT 2 (1.8%) 63 (21.1%) p < 0.0001 70 (21.5%) p < 0.0001
TG 42 (36.8%) 157 (52.7%) 170 (52.1%)
GG 70 (61.4%) 78 (26.2%) 86 (26.4%)
NA 5 3 47
C3 rs2230199 C?G
GG 4 (3.6%) 9 (3.0%) p = 0.437 11 (3.4%) p = 0.422
GC 27 (24.3%) 92 (30.8%) 101 (30.9%)
CC 80 (72.1%) 198 (66.2%) 215 (65.7%)
NA 8 2 46
Tobacco
Current smoker 3 (2.6%) 50 (17.5%) p < 0.0001 64 (18.0%) p < 0.0001
Ex-smoker 25 (21.9%) 81 (28.3%) 95 (26.8%)
Never smoker 86 (75.4%) 155 (54.2%) 196 (55.2%)
NA 5 15 18
NA = data not available.
Table 2. Age of onset of exudative age-related macular degeneration (AMD).
Polymorphisms
Age of Onset of Exudative AMD
Years, median (range) Mann–Whitney U test
IL-8 rs4073 A?T
AA 71.7 (55.5–84.3) AA versus AT and TT
AT 75.5 (56.1–91.2) p = 0.009
TT 75.6 (53.1–87.6)
CFH rs1061170 T?C
CC 73.8 (53.1–91.2) CC versus CT and TT
TC 76.3 (59.4–87.6) p = 0.016
TT 76.2 (63.9–87.0)
ARMS2 rs10490924 G?T
TT 71.3 (55.5–87.6) TT versus TG and GG
GT 76.2 (53.1–91.2) p = 0.001
GG 75.8 (54.5–88.1)
C3 rs2230199 C?G
GG 74.7 (63.1–85.1) CC versus CG and GG
CG 74.8 (55.4–87.6) p = 0.267
CC 75.8 (53.1–91.2)
Tobacco
Current smoker 70.1 (54.5–82.3) Current versus never
and ex-smokersEx-smoker 76.5 (62.8–88.1)
Never Smoker 75.0 (53.1–91.2) p = 0.002
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To take into account the diﬀerence
in the age distribution in the groups of
exudative AMD patients and control
subjects, the Cox proportional hazards
models were used (Fig. 1) as described
in the methods section. First, both
patients with exudative AMD and
control subjects were included to esti-
mate the eﬀects of the studied variables
on the prevalence of exudative AMD
(Fig. 1, left column). Age was used as
time scale: age at the onset of exudative
AMD for the cases and age at data
collection for the controls. Patients
with dry AMD were not included.
The estimated eﬀects remained similar
compared to the univariate analyses
and multivariate models built with the
GLZ procedure, signiﬁcant eﬀects seen
with the CFH rs1061170 [TC versus
TT, hazard ratio (HR) = 1.7, p = 0.021
and CC versus TT, HR = 2.6,
p < 0.0001], ARMS2 rs10490924 (GT
versus GG, HR = 1.6, p = 0.024 and
TT versus GG, HR = 3.3, p < 0.0001)
and smoking (ex- versus never smok-
ers, HR = 1.4, CI 1.06 –1.90, p = 0.020
and current versus never smokers,
HR = 2.4, p < 0.0001). Then, the
eﬀects of the studied factors on the
age of onset of exudative AMD were
analysed separately in the group of
patients with the exudative disease
(Fig. 1, middle column). The homozy-
gous risk genotypes AA in IL-8 rs4073
(HR = 1.7, p = 0.005), CC in CFH
rs1061170 (HR = 1.3, p = 0.05) and
TT in ARMS2 rs10490924 (HR = 1.8,
p = 0.0003) were associated with the
younger onset of exudative AMD,
whereas the eﬀects of the heterozygous
genotypes did not diﬀer from the non-
risk homozygous genotypes. Also, cur-
rent smoking was signiﬁcantly associ-
ated with the younger age at the onset
of the disease (HR = 1.6, p = 0.005),
whereas ex-smokers did not diﬀer from
never smokers. No signiﬁcant associa-
tions were detected with the genotypes
of C3 rs2230199.
We considered the possibility of a
more delayed diagnosis of exudative
AMD before the era of widely used
OCTs and availability of more eﬀective
treatments and analysed the data of
patients diagnosed during the last
5 years of data collection (n = 101,
between April 2005 and April 2010)
separately. The eﬀects of the studied
SNPs and tobacco smoking on the
diagnosis of exudative AMD remained
the same when the subgroup was anal-
ysed with the control subjects (data not
shown). When only the patients with
exudative AMD were included, the
eﬀect of the IL-8 rs4073 on the age at
diagnosis, however, was even more
pronounced (HR = 2.9, p = 0.00031),
and became the most signiﬁcant of the
factors associated with the earlier onset
of the exudative AMD (Fig. 1, right
column).
The homozygous risk genotypes and
current smoking had also a cumulative
eﬀect on the age of onset of exudative
AMD. The best correlation with the
age of onset was found when the sum
of the homozygous risk genotypes of IL-
8, CFH and ARMS2, and smoking
(current smoker = 1 point, ex- or non-
smoker = 0 points) were calculated for
each patient (Spearman’s rho 0.348,
p < 0.0001). Signiﬁcant diﬀerence in the
age of onset existed between the patients
with zero risk factors (n = 84, median
age 77.6 years, range 62.8–87.6 years)
compared with the patients with one
(n = 107, 74.5 years, 53.1–91.2 years,
p = 0.0001), two to four (n = 52,
71.8 years, 54.5–83.8 years, p < 0.0001)
or three to four (n = 6, 68.3 years, 63.3–
69.8 years, p = 0.0002) risk factors. A
signiﬁcant diﬀerence existed also
between the patients with one and two
(n = 46, 72.9 years, 54.5–83.8 years,
p = 0.015) risk factors (Fig. 2).
No clear associations were found
between the CNV lesion types and
studied SNPs or tobacco smoking.
Minimally classic lesions, however,
were less frequent in patients with the
homozygous TT risk genotype of
ARMS2 (p = 0.001). The type of the
exudative lesion had no eﬀect on the
age of onset of exudative AMD. Gen-
der had no eﬀect in any of the analyses.
No interactions between the studied
factors were found.
Discussion
In this study, we could show the earlier
onset of exudative AMD to be associ-
ated not only with current smoking and
the homozygous risk genotypes of the
CFH rs1061170 and ARMS2
rs10490924 as reported earlier in other
populations (Shuler et al. 2007, 2008;
Keilhauer et al. 2013; Lechanteur et al.
2015), but also with the risk genotype
AA of the IL-8 rs4073. Out of these
factors, only the AA genotype of IL-8
rs4073 is not a well-established risk
factor for AMD and did not associate
with the overall prevalence of AMD in
our material. The IL-8 rs4073 genotype
may thus be connected with the mech-
anisms leading to the growth of CNV
in the AMD disease process.
The IL-8 rs4073 A?T has been
associated with variations in IL-8 pro-
duction, and signiﬁcantly higher levels
of circulating and mucosal IL-8 have
been detected in patients carrying the A
allele or the AA homozygous genotype
in IL-8 rs4073 (Hull et al. 2000; Ohy-
auchi et al. 2005; Taguchi et al. 2005;
Hildebrand et al. 2007). In addition to
being a powerful inﬂammatory cyto-
kine, a chemotactic factor for migra-
tory immune cells and an activating
factor for neutrophilic granulocytes,
Table 3. Multivariate model built with the generalized linear model procedure of SPSS 22 to
estimate the eﬀects of studied variables on the age of onset of exudative AMD.
Parameter B SE
95% Wald CI Hypothesis Test
Lower Upper Wald chi-square p-value
IL-8 rs4073 A?T
AA 2.502 1.1448 4.746 0.258 4.776 0.029
AT or TT Reference
CFH rs1061170 T?C
CC 2.171 0.8170 3.773 0.570 7.064 0.008
CT or TT Reference
ARMS rs10490924 G?T
TT 2.973 0.9811 4.896 1.050 9.181 0.002
TG or GG Reference
Smoking
Current smoker 3.885 1.0613 5.965 1.805 13.398 0.0003
Non- or ex-smoker Reference
Intercept 2.240 0.5966 1.071 3.409 14.100 <0.0001
Dependent variable: age – 75.0 years (median age of the exudative study patients).
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Fig. 1. The eﬀects of single nucleotide polymorphisms (SNPs) IL-8 rs4073, CFH rs1061170 and ARMS2 rs10490924, as well as smoking, were
estimated with Cox proportional hazards models in exudative AMD patients together with control subjects (left column), in all patients with
exudative AMD (middle column) and in exudative AMD patients diagnosed within the last 5 years of data collection (right column). n, number of
cases available in the analysis (no missing values).
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IL-8 is a potent proangiogenic factor.
IL-8 is expressed not only by the cells
of immune system but also by vascular
endothelial and retinal pigment epithe-
lial (RPE) cells. It has a critical role in
vascular formation both in physiolog-
ical and pathological conditions (Bel-
perio et al. 2000). Expression of IL-8 is
upregulated in response to various
stimuli, including CRP (Wang et al.
2010), oxidative stress (DeForge et al.
1993), saturated fatty acids (Stentz &
Kitabchi 2006), preoxidized photore-
ceptor outer segments (Higgins et al.
2003), amyloid-b (Kurji et al. 2010)
and angiopoietin-1 (Abdel-Malak et al.
2008). IL-8 induces angiogenesis
through both VEGF-dependent and
VEGF-independent pathways and
increases endothelial permeability
(Mizukami et al. 2005; Martin et al.
2009). IL-8 receptors CXCR1 and
CXCR2 are expressed in endothelial
cells. The activation of the CXCR2-
receptor elevates the levels of intracel-
lular VEGF and enhances VEGF
secretion (Martin et al. 2009). The
activated CXCR2 is also capable of
forming a complex with the VEGF
receptor, VEGFR2, and causes trans-
activation of the VEGF receptor with-
out the presence of VEGF (Petreaca
et al. 2007). In aged cells, disturbance
of calcium homeostasis may lead to
induced IL-8 gene expression and IL-8
secretion (Yang et al. 2015). Chronic
oxidative stress has also been found to
trigger the RPE cells to produce higher
levels of IL-8 stimulating both inﬂam-
mation and angiogenesis, which, in
turn, may lead to the development of
CNV and exudative AMD (Zhu et al.
2009).
In our data, the associations found
between the presence of AMD lesions
and the known genetic risk factors for
AMD, CFH rs1061170, ARMS2
rs10490924 and current smoking were
clear (Christen et al. 1996; Seddon
et al. 1996, 2013; Edwards et al. 2005;
Haines et al. 2005; Jakobsdottir et al.
2005; Klein et al. 2005; DeWan 2006;
Yang et al. 2006; Maller et al. 2007;
Yates et al. 2007). We could not, how-
ever, show any association between the
prevalence of AMD and the risk geno-
type of IL-8 rs4073. The A allele in IL-
8 SNP rs4073 has previously been
associated with an increased risk of
AMD in Caucasian population in Brit-
ain (Goverdhan et al. 2008). Also, the
IL-8 rs2227306 T?C (+781 C/T) has
been associated with an increased risk
of developing exudative AMD in Tai-
wan Chinese and in Italian populations
(Tsai et al. 2008; Ricci et al. 2013). In
Europeans, a strong linkage disequilib-
rium exists between the IL-8 SNPs
rs4073 and rs2227306 (Hull et al.
2001; Ricci et al. 2013), and therefore,
we would have expected to ﬁnd a same
kind of association with the IL-8
rs4073 in our material. Our sample
size, however, is limited, and with the
power of 0.8 only diﬀerences over 13%
in allele frequencies between the groups
could be detected. The diﬀerences
reported earlier have been less than
that both in the British and in the
Italian populations (Goverdhan et al.
2008; Ricci et al. 2013). The IL-8
rs2227306 may be the SNP that is,
after all, the main functional polymor-
phism responsible for the enhanced
interaction with the transcription fac-
tor binding complex and the higher
levels of secreted IL-8 and may there-
fore show somewhat stronger associa-
tions with pathologies than the IL-8
rs4073 (Hacking et al. 2004). Despite
our limited sample size, however, the
younger age of onset of the exudative
AMD was quite clearly associated not
only with the known risk genotypes in
the CFH rs1061170 and ARMS2
rs10490924 and current smoking but
also with the AA genotype of IL-8
rs4073.
The younger age of onset of the
disease in the exudative AMD patients
was associated only with the homozy-
gous, not heterozygous risk genotypes
in the IL-8 rs4073, CFH rs1061170 and
ARMS2 rs10490924. It was also asso-
ciated with only current smoking, not
ex-smoking compared with non-smok-
ing behaviour. The associations with
the prevalence of AMD, on the other
hand, resemble more of a dose–
response pattern with higher hazard
ratios associated also with heterozy-
gous genotypes and ex-smoking com-
pared with non-risk homozygous
genotypes and non-smoking. The same
kind of phenomenon has also been seen
in the previous studies showing the
homozygous risk genotypes of CFH
rs1061170 and ARMS2 rs10490924 and
tobacco smoking to be associated with
the younger onset of exudative AMD
(Shuler et al. 2007, 2008; Keilhauer
et al. 2013; Lechanteur et al. 2015).
One possible explanation could be that
when in the analyses of the age of onset
only diseased subjects are included, the
protective eﬀects of the non-risk geno-
types and non-smoking behaviour are
not fully seen when healthy controls
are not represented.
The limitations of this study are its
retrospective nature, the relatively
small sample size, the estimate of onset
of the disease being based on the
medical records and the diagnosis
being based on clinical ﬁndings and
angiograms in the era before OCTs.
The study population also represents a
combined sample of subjects of our
previous studies. The results, especially
the distinct diﬀerence between the
eﬀects of IL-8 rs4073 on the prevalence
of AMD and on the age of onset of
Fig. 2. The sum of homozygous risk genotypes in IL-8, CFH and ARMS2, and current smoking
on the age of onset of exudative AMD (*p < 0.05, ***p < 0.001, ****p < 0.0001, Mann–Whitney
U-test).
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exudative disease, need to be conﬁrmed
in larger and independent patient mate-
rials.
The association of the IL-8 rs4073
A?T with the earlier onset of exuda-
tive AMD increases the evidence of the
role of IL-8 in the exudative AMD
disease process. The results of this
study suggest that the IL-8 polymor-
phism may have a stronger eﬀect on the
age of onset of exudative AMD than
on the risk of developing AMD. An
explanation for that could be that the
IL-8 enhances vascular leakage. An
increased tendency to develop retinal
oedema with higher IL-8 levels could
lead to more symptomatic lesions and
earlier diagnosis of the disease. Also,
increased local IL-8 production may
augment the proinﬂammatory eﬀects
of the established AMD risk factors
and link inﬂammation and angiogene-
sis in the transformation of a dry AMD
lesion into the exudative phenotype.
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